Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of resmetirom in adults with NASH and fibrosis
2024-510626-89-00Phase 3Authorised
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Madrigal Pharmaceuticals. Primary endpoints: Week 52 dual primary endpoints and Time to composite clinical outcome event. Planned start Apr 2024; status: authorised.
02
Drugs
resmetirom
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2024-510626-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510626-89-00.